Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8466617 | 0.89 | DGAT1 (0.38) | MAPK1DGAT1MEN1KMT2A | |
| SCHEMBL5075951 | 0.85 | BTK (0.36) | MAPK1DGAT1MEN1KMT2ALMNA | |
| SCHEMBL1706674 | 0.82 | MAPK1 (0.40) | MAPK1DGAT1MEN1KMT2ALMNA | |
| SCHEMBL1577536 | 0.78 | MAPK1 (0.38) | MAPK1MEN1KMT2ALMNACYP2C9 | |
| SCHEMBL5078529 | 0.78 | MAPK1 (0.38) | MAPK1MEN1KMT2ALMNACYP2C9 | |
| SCHEMBL3675536 | 0.76 | MAPK1 (0.33) | MAPK1DGAT1MEN1KMT2ALMNA | |
| SCHEMBL5075913 | 0.76 | MAPK1 (0.39) | MAPK1MEN1KMT2A | |
| SCHEMBL295935 | 0.75 | MAPK1 (0.41) | MAPK1DGAT1MEN1KMT2AHRH3 | |
| SCHEMBL11231864 | 0.71 | MAPK1 (0.38) | MAPK1MEN1KMT2AHRH3 | |
| SCHEMBL12994214 | 0.70 | MAPK1 (0.35) | MAPK1DGAT1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1731499-B1 | PROCESS FOR PRODUCING 1,2-CIS-2-FLUOROCYCLOPROPANE-1-CARBOXYLIC ESTER COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2014-10-01 | — | — | EP | disclosed |
| US-7381833-B2 | Process for producing 1,2-cis-2-fluorocyclopropane-1-carboxylic ester compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-06-03 | — | — | US | disclosed |
| US-20070191626-A1 | Process for producing 1,2-cis-2 fluorocyclopropane- 1carboxylic ester compound | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1731499-A1 | PROCESS FOR PRODUCING 1,2-CIS-2-FLUOROCYCLOPROPANE-1CARBOXYLIC ESTER COMPOUND | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191626-A1 | Process for producing 1,2-cis-2 fluorocyclopropane- 1carboxylic ester compound | HACL2, B2M, CA1 | MAPK1 1093/4885DGAT1 1557/4885MEN1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.